-
Which African countries are leading vaccine innovation?
South Africa and Nigeria are among the leaders in vaccine development in Africa. South Africa is conducting clinical trials for a fully manufactured cholera vaccine, aiming for approval by 2028. Nigeria is progressing with a Lassa fever vaccine, supported by global partners like CEPI. These efforts highlight Africa's growing capacity to produce vaccines locally, reducing dependence on imports.
-
What are the main challenges to vaccine manufacturing in Africa?
Vaccine manufacturing in Africa faces hurdles such as limited clinical trial capacity, high costs, and infrastructure gaps. Many countries lack the facilities and expertise needed for large-scale vaccine production. Additionally, regulatory frameworks and funding can slow down development. Despite these challenges, initiatives are underway to build a resilient vaccine ecosystem across the continent.
-
How will local vaccines change healthcare in Africa?
Locally produced vaccines can improve healthcare by ensuring quicker access during outbreaks, reducing reliance on imports, and lowering costs. They also enable region-specific solutions tailored to local health issues. As vaccine self-reliance grows, African countries can better control diseases like cholera and Lassa fever, ultimately strengthening health security.
-
What partnerships are supporting vaccine self-reliance in Africa?
Global organizations like CEPI are partnering with African governments and local stakeholders to boost vaccine research and manufacturing. These collaborations provide funding, technical expertise, and infrastructure support. Such partnerships are crucial for building sustainable vaccine production capabilities across the continent.
-
When can we expect more African-made vaccines to be available?
While some vaccines like the cholera vaccine in South Africa are expected to be approved by 2028, broader availability depends on overcoming current challenges. As infrastructure improves and partnerships strengthen, more African-made vaccines are likely to reach the market in the coming years, enhancing regional health resilience.